Sera Prognostics reported a significant decline in quarterly revenue, dropping to $10,000 from $24,000 year-over-year, while narrowing its net loss to $7.9 million. The company’s annual revenue increased modestly to $81,000, with operating expenses holding steady at $36.6 million. Notably, the publication of the PRIME study, which demonstrated a reduction in preterm births, is expected to drive engagement with payers and enhance the company’s credibility in the market.
This financial performance underscores Sera Prognostics’ strategic shift towards commercialization, as management reallocates resources from R&D to expand its network of providers and payers. The company is actively pursuing coverage pathways across 13 states and aims to operate five to seven partner programs by year-end. The anticipated European market entry, pending CE marking, could further bolster growth prospects.
Investors should monitor Sera Prognostics’ progress in converting payer discussions into coverage decisions, as successful execution of its commercialization strategy could lead to a gradual revenue build. For a deeper dive into the company’s plans and performance, I recommend checking out the full article.
Source: fool.com